HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons

The review analyzes the potential advantages and problems associated with using HIF prolyl hydroxylase inhibitors as a treatment for COVID-19. HIF prolyl hydroxylase inhibitors are known to boost endogenous erythropoietin (Epo) and activate erythropoiesis by stabilizing and activating the hypoxia in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Pharmacol
Hlavní autoři: Poloznikov, Andrey A., Nersisyan, Stepan A., Hushpulian, Dmitry M., Kazakov, Eliot H., Tonevitsky, Alexander G., Kazakov, Sergey V., Vechorko, Valery I., Nikulin, Sergey V., Makarova, Julia A., Gazaryan, Irina G.
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2021
Témata:
Pharmacology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7878396/
https://ncbi.nlm.nih.gov/pubmed/33584306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.621054
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky